GlaxoSmithKline plc (GSK) Received Hold Rating from Shore Capital

GlaxoSmithKline plc (GSK) Received Hold Rating from Shore Capital

GlaxoSmithKline plc (LON:GSK)‘s stock had its “hold” rating reissued by Shore Capital in a report issued on Friday.

Other analysts have also recently issued reports about the company. Liberum Capital reiterated a “buy” rating and set a GBX 1,900 ($24.41) price target on shares of GlaxoSmithKline plc in a research report on Thursday, March 9th. Goldman Sachs Group Inc reiterated a “buy” rating and set a GBX 1,900 ($24.41) price target on shares of GlaxoSmithKline plc in a research report on Wednesday. Bryan, Garnier & Co reiterated a “buy” rating and set a GBX 1,750 ($22.48) price target on shares of GlaxoSmithKline plc in a research report on Wednesday. Beaufort Securities increased their price target on GlaxoSmithKline plc from GBX 1,750 ($22.48) to GBX 2,000 ($25.69) and gave the stock a “buy” rating in a research report on Thursday. Finally, Jefferies Group LLC dropped their price target on GlaxoSmithKline plc from GBX 1,850 ($23.76) to GBX 1,800 ($23.12) and set a “buy” rating on the stock in a research report on Thursday, April 20th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of GBX 1,751.77 ($22.50).

GlaxoSmithKline plc (GSK) opened at 1714.50 on Friday. The firm’s market capitalization is GBX 83.77 billion. The company has a 50-day moving average price of GBX 1,619.26 and a 200 day moving average price of GBX 1,591.69. GlaxoSmithKline plc has a 1-year low of GBX 1,363.00 and a 1-year high of GBX 1,745.56.

The firm also recently announced a dividend, which will be paid on Thursday, July 13th. Stockholders of record on Thursday, May 11th will be given a GBX 19 ($0.24) dividend. The ex-dividend date of this dividend is Thursday, May 11th. This represents a dividend yield of 1.21%.

In other GlaxoSmithKline plc news, insider Dominic Redfern bought 230 shares of the firm’s stock in a transaction dated Thursday, April 13th. The stock was acquired at an average price of GBX 1,639 ($21.05) per share, with a total value of £3,769.70 ($4,842.26). Also, insider Moncef Slaoui bought 56 shares of the firm’s stock in a transaction dated Tuesday, March 7th. The stock was acquired at an average cost of GBX 2,072 ($26.62) per share, with a total value of £1,160.32 ($1,490.46). In the last ninety days, insiders bought 718 shares of company stock valued at $1,183,024.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:GSK”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment